Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China.

Yichen Zhang, Yuxuan Wei, Huangqianyu Li, Yixuan Chen, Yiran Guo, Sheng Han, Luwen Shi, Xiaodong Guan

PharmacoEconomics 2022 Jul

filter terms:

costs analysis (2)

drug costs (1)

free (3)

humans (1)

patients (1)

prices (9)

therapies (2)

Sizes of these terms reflect their relevance to your search.

High prices of anticancer medicines have increased the economic burden for both patients and health insurance systems. Since 2017, China has implemented national price negotiations for medicines, relying on evidence from health technology assessments. We aim to assess the relation between negotiated price and value of anticancer medicines listed in China's National Reimbursement Drug List (NRDL). For all price-negotiated anticancer medicines and corresponding indications listed in the latest NRDL between 2017 and 2020, we collected their clinical outcomes data, including overall survival (OS) and progression-free survival (PFS), in supporting trials. Pearson correlation coefficient was calculated to estimate the association between the daily cost and clinical benefit of each indication. In total, 75 indications of 46 branded anticancer medicines were included for analysis. The median daily costs for the anticancer therapies that had gone through negotiation in 2017-2020 were US$87.6, US$71.8, US$58.9, and US$39.7, respectively. For indications supported by randomized trials, no correlation between daily costs and OS and PFS benefit of the price-negotiated cancer therapies was observed (N = 41, r = -0.05, and N = 49, r = 0.04, respectively). For cancer indications newly listed in NRDL in 2020, the association between their daily cost and OS benefit was -0.78 (N = 4, p = 0.221) and 0.01 (N = 8, p = 0.986) before and after the price negotiation. Though the negotiation policy decreased prices of anticancer medicines in China, no statistically significant correlation was observed between their daily costs and clinical benefits. A more transparent and credible pricing approach needs to be established to promote value-based anticancer medicines and healthcare system efficiency. © 2022. The Author(s).

Citation

Yichen Zhang, Yuxuan Wei, Huangqianyu Li, Yixuan Chen, Yiran Guo, Sheng Han, Luwen Shi, Xiaodong Guan. Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China. PharmacoEconomics. 2022 Jul;40(7):715-724